{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T02:22:48Z","timestamp":1792808568172,"version":"4.5.0"},"reference-count":14,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:p>Bone marrow failure syndrome (BMFS) type 3 is a rare genetic heterogeneous disorder, considered to be one of Inherited BMFSs related to ribosomopathies. It caused by a novel Homozygous variant in <jats:italic toggle=\"yes\">DNAJC21<\/jats:italic> gene, which affects cytoplasmic maturation of 60S ribosomal, leading to increase cell death, and inhibits cellular proliferation causing shwachman-diamond Syndrome-like syndrome. Only 15 cases of BMFS type 3 have been published in the literature. Therefore, the full phenotypic spectrum and the experience of hematopoietic stem cell transplantation (HSCT) are limited. Herein, we report an uncomplicated HSCT from human leukocyte antigen-identical sibling for a BMFS-3 patient at 22 months of age, who suffered from chronic diarrhea, severe failure to thrive and cytopenia required transfusions. We used a reduced intensity conditioning regimen including fludarabine, low-dose cyclophosphamide, and antithymocyte globulin with cyclosporine for prevent graft versus host disease. This regimen was safe and sufficient to achieve rapid engraftment without significant toxicity. Although, Mixed chimerism between 80% and 90% was observed since day +30, she gained 2\u2009kg during 12 months post-transplant and no need for transfusions has been reported any more. Thus, we recommend HSCT with fludarabine-based reduced intensity conditioning regimen in this syndrome as progressive cytopenia occurs and an human leukocyte antigen-matched family donor is available.<\/jats:p>","DOI":"10.1097\/mph.0000000000002374","type":"journal-article","created":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T12:31:34Z","timestamp":1640176294000},"page":"e1050-e1052","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["Fludarabine-based Reduced Intensity Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation in a Pediatric Patient With Bone Marrow Failure Syndrome Type 3"],"prefix":"10.1097","volume":"44","author":[{"given":"Dima","family":"Barhoom","sequence":"first","affiliation":[{"name":"Pediatric Cell and Gene Therapy Research Center; Gene, Cell and Tissue Research Institute, Tehran University of Medical Sciences, Tehran, Iran"},{"name":"Pediatric Hematopoietic Stem Cell Transplant Center, Children\u2019s Hospital, Damascus University, Damascus, Syria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashin","family":"Mohseni","sequence":"additional","affiliation":[{"name":"Pediatric Cell and Gene Therapy Research Center; Gene, Cell and Tissue Research Institute, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Behfar","sequence":"additional","affiliation":[{"name":"Pediatric Cell and Gene Therapy Research Center; Gene, Cell and Tissue Research Institute, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir A.","family":"Hamidieh","sequence":"additional","affiliation":[{"name":"Pediatric Cell and Gene Therapy Research Center; Gene, Cell and Tissue Research Institute, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,12,22]]},"reference":[{"key":"R1-20250804","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ajhg.2016.05.002","article-title":"DNAJC21 mutations link a cancer-prone bone marrow failure syndrome to corruption in 60S ribosome subunit maturation","volume":"99","author":"Tummala","year":"2016","journal-title":"Am J Hum Genet"},{"key":"R3-20250804","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1182\/blood-2016-08-735431","article-title":"Biallelic mutations in DNAJC21 cause Shwachman-Diamond syndrome","volume":"129","author":"Dhanraj","year":"2017","journal-title":"Blood"},{"key":"R4-20250804","first-page":"blood.202101091","article-title":"Somatic uniparental disomy mitigates the most damaging EFL1 allele 1 combination in Shwachman-Diamond syndrome 2","volume":"11","author":"Lee","year":"2021","journal-title":"Blood"},{"key":"R5-20250804","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jbior.2017.09.002","article-title":"Advances in biological regulation molecular basis of the human ribosomopathy Shwachman-Diamond syndrome","volume":"67","author":"Warren","year":"2018","journal-title":"Adv Biol Regul"},{"key":"R6-20250804","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.hoc.2018.04.006","article-title":"Diagnosis, treatment, and molecular pathology of shwachman-diamond syndrome","volume":"32","author":"Nelson","year":"2018","journal-title":"Hematol Oncol Clin North Am"},{"key":"R7-20250804","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/cge.13370","article-title":"Refining the phenotype associated with biallelic DNAJC21 mutations","volume":"94","author":"D\u2019Amours","year":"2018","journal-title":"Clin Genet"},{"key":"R8-20250804","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1182\/blood-2017-09-806489","article-title":"A landscape of germ line mutations in a cohort of inherited bone marrow failure patients","volume":"131","author":"Bluteau","year":"2018","journal-title":"Blood"},{"key":"R10-20250804","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1182\/asheducation-2017.1.88","article-title":"Inherited bone marrow failure syndromes: considerations pre- and posttransplant","volume":"2017","author":"Alter","year":"2017","journal-title":"Hematology"},{"key":"R11-20250804","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s12185-016-1951-0","article-title":"Allogeneic hematopoietic stem cell transplantation for inherited bone marrow failure syndromes","volume":"103","author":"Hugues","year":"2016","journal-title":"Int J Hematol"},{"key":"R14-20250804","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/j.bbmt.2017.05.022","article-title":"Share late effects screening guidelines after hematopoietic cell transplantation for inherited bone marrow failure syndromes: consensus statement from the second pediatric blood and marrow transplant consortium international conference on late effects after pediatric HCT","volume":"23","author":"Dietz","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"R15-20250804","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1038\/bmt.2013.35","article-title":"Reduced intensity conditioning is effective for hematopoietic SCT in dyskeratosis congenita-related BM failure","volume":"48","author":"Ayas","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"R16-20250804","doi-asserted-by":"crossref","first-page":"109","DOI":"10.5144\/1658-3876.2011.109","article-title":"Long-term results of non-fludarabine versus fludarabine-based stem cell transplantation without total body irradiation in Fanconi anemia patients","volume":"4","author":"Hamidieh","year":"2011","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"R17-20250804","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/bmt.2015.277","article-title":"Long-term outcomes of fludarabine, melphalan and antithymocyte globulin as reduced-intensity conditioning regimen for allogeneic hematopoietic stem cell transplantation in children with primary immunodeficiency disorders: a prospective single center study","volume":"51","author":"Hamidieh","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"R18-20250804","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1007\/s00277-017-3041-7","article-title":"Disease-specific hematopoietic stem cell transplantation in children with inherited bone marrow failure syndromes","volume":"96","author":"Li","year":"2017","journal-title":"Ann Hematol"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000002374","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T20:02:53Z","timestamp":1754337773000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000002374"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,22]]},"references-count":14,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000002374","relation":{},"ISSN":["1077-4114"],"issn-type":[{"value":"1077-4114","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12,22]]},"assertion":[{"value":"2021-08-23","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-10-19","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}